4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow

Impact · against what's priced in

The article provides a positive outlook for MLYS, INSM, LYEL, and NKTR, driven by sector-wide tailwinds and specific clinical success for Mineralys Therapeutics. Because these stocks have already returned over 50% this year, much of the momentum is already reflected in the price, though MLYS's specific trial endpoints provide concrete fundamental support.

MLYS+0.40

No priced-in read yet